Online citations, reference lists, and bibliographies.
← Back to Search

Paclitaxel- And Lapatinib-loaded Lipopolymer Micelles Overcome Multidrug Resistance In Prostate Cancer

Feng Li, M. Danquah, S. Singh, H. Wu, R. Mahato
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Paclitaxel is a potent chemotherapeutic agent for treating refractory prostate cancer. However, its prolonged treatment develops multidrug resistance. Since lapatinib interacts with and inhibits P-gp activity, our objective was to determine whether the combination therapy of these two drugs can synergistically treat resistant prostate cancer. Our recently synthesized lipopolymer, poly(ethylene glycol)-block-poly(2-methyl-2-carboxylpropylene carbonate-graft-dodecanol) (PEG–PCD), was used to efficiently load both drugs into PEG–PCD micelles since they are hydrophobic. Lapatinib inhibited P-gp function but not its expression. Co-treatment of DU145-TXR cells with 0.5 μM paclitaxel and 5 μM lapatinib resulted in up to 138-fold reversal compared to paclitaxel alone. These formulations killed almost 70% and 80% of DU145-TXR cells when 0.5 μM paclitaxel was combined with lapatinib at a dose of 1 and 5 μM, respectively, while monotherapy had no effect. Combination therapy induced apoptosis and cell cycle arrest at mitotic phase. Xenograft tumor growth in athymic nude mice was significantly regressed when PEG–PCD micelles carrying lapatinib and paclitaxel were given intravenously twice a week. Furthermore, this combination therapy synergistically decreased antiangiogenic activity compared to the control or their monotherapy. In conclusion, lipopolymeric micelles carrying lapatinib and paclitaxel have the potential to treat resistant prostate cancer and can successfully deliver drugs to tumors while minimizing toxic effects associated with solubilizing agents.
This paper references
10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J
Paclitaxel‐induced cell death
T. Wang (2000)
10.1158/0008-5472.CAN-04-4292
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Y. Liu (2005)
10.1038/nrd1984
Targeting multidrug resistance in cancer
G. Szakács (2006)
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
C. Erlichman (2001)
10.1016/j.jconrel.2009.12.028
Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100.
F. Li (2010)
10.1007/s10637-009-9266-0
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines
D. Collins (2009)
10.1016/J.JCONREL.2007.07.008
What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core.
Tatsuhiro Yamamoto (2007)
10.1200/JCO.2008.16.2578
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
A. Di Leo (2008)
10.1159/000071510
Multidrug Resistance in Prostate Cancer
J. V. van Brussel (2003)
10.1016/S0168-3659(99)00248-5
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
10.1201/b13198-79
Tumors
(1828)
10.1002/pros.20991
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs
C. Sánchez (2009)
10.1021/bm100561v
Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery.
F. Li (2010)
10.1093/jnci/djn123
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
X-b Li (2008)
10.1093/JNCI/84.24.1909
Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
A. Rahman (1992)
10.1158/0008-5472.CAN-08-0499
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Chun-ling Dai (2008)
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate
C Sanchez (2009)
10.1002/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8
Polymeric micellar paclitaxel phosphorylates Bcl‐2 and induces apoptotic regression of androgen‐independent LNCaP prostate tumors
S. Leung (2000)
10.1016/S0022-5347(17)35838-X
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
G. Theyer (1993)
10.1021/BC040297G
Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
K. Greish (2005)
10.1158/0008-5472.CAN-08-2747
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
X. Dong (2009)
Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules
F Li (2010)
10.1097/COC.0b013e3181beac33
A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
S. Sridhar (2010)
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
D. Belotti (1996)
10.1245/s10434-006-9227-1
Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
N. Steeghs (2006)
10.1186/1475-2867-8-3
Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling
G. Shaw (2007)
an update of recent developments
N Steeghs (2011)
10.1016/j.bcp.2009.08.021
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
Yehong Kuang (2010)
10.1007/s10637-010-9482-7
Modulation of P-gp expression by lapatinib
Gráinne Dunne (2010)
10.1016/S0168-3659(98)00009-1
HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.
T. Minko (1998)
10.1016/J.BCP.2006.07.022
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
H. Coley (2006)
10.1016/j.clinthera.2008.08.008
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
P. Medina (2008)
10.1016/j.addr.2010.11.005
Extravasation of polymeric nanomedicines across tumor vasculature.
M. Danquah (2011)
10.1158/0008-5472.CAN-09-4264
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
A. Carcaboso (2010)
Expression of multidrug resistance proteins in
C Sanchez



This paper is referenced by
10.21007/etd.cghs.2012.0062
Nanotherapies for treating prostate cancer
M. Danquah (2012)
10.1016/j.apmt.2019.100492
Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer
Y. Chang (2020)
10.1016/j.jconrel.2020.01.001
Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy.
Anne McMahon (2020)
10.1007/s11095-012-0881-7
Formulation and Characterization of Polyester/Polycarbonate Nanoparticles for Delivery of a Novel Microtubule Destabilizing Agent
Vaibhav Mundra (2012)
10.1007/s11095-012-0737-1
Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer
M. Danquah (2012)
10.2174/0929867325666180607094856
Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.
Tijana Stankovic (2018)
10.1002/jps.24234
A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Y. Wei (2015)
Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance In Vitro Using In Silico Identified Novel Compounds
A. Nanayakkara (2019)
10.3109/10837450.2014.965323
Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation
Pooya Dehghan Kelishady (2015)
10.3892/ijo.2016.3560
Exosome-derived microRNAs contribute to prostate cancer chemoresistance.
Jing Li (2016)
10.1039/c3cp51471d
NMR study of the supramolecular structure of dual drug-loaded poly(butylcyanoacrylate) nanoparticles.
M. Simeonova (2013)
10.3390/pharmaceutics11040169
Cytotoxic Effect of Paclitaxel and Lapatinib Co-Delivered in Polylactide-co-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells
A. Zajdel (2019)
10.3390/nano10030561
Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation
Shani L. Levit (2020)
10.1080/03639045.2016.1254238
In vitro and in vivo evaluation of paclitaxel–lapatinib-loaded F127 pluronic micelles
Pouya Dehghankelishadi (2017)
10.1371/journal.pone.0040021
Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway
S. Singh (2012)
10.3791/54338
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles.
F. Li (2016)
10.1016/j.jconrel.2015.10.018
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hongxiang Hu (2015)
10.1007/s13346-015-0222-6
Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation
Dwayne Koot (2015)
10.20517/2574-1209.2019.36
Tumour vasculature targeted anti-cancer therapy
Debabrata G Dastidar (2020)
Delivery of small molecule and RNA for the treatment of type 1 diabetes and prostate cancer
Di Wen (2017)
10.1016/j.jconrel.2017.12.016
Lipid‐polymer hybrid nanocarriers for delivering cancer therapeutics
Tushar Date (2018)
10.1016/j.ajps.2019.06.001
Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
Xiaohan Zhou (2020)
10.1080/17425247.2018.1449832
Lapatinib nano-delivery systems: a promising future for breast cancer treatment
G. Bonde (2018)
10.1088/1361-6528/ab94dc
Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
T. Qin (2020)
10.3390/cells8010074
Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells
Takeshi Namekawa (2019)
10.1002/ADFM.201300793
Co-delivery of Cell-permeable Chimeric Apoptosis AVPIR8 Peptide/p53 DNA for Cocktail Therapy
H. Wang (2013)
10.1021/mp400687w
Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
H. Wang (2014)
10.1002/POLA.26392
Lactic Acid- and Carbonate-Based Crosslinked Polymeric Micelles for Drug Delivery
M. Danquah (2013)
10.1002/adhm.202000564
Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles.
Jason V Gregory (2020)
10.3390/molecules25030604
Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
J. Wang (2020)
Semantic Scholar Logo Some data provided by SemanticScholar